Teva Acquires BioXcel Neuroscience Assets Through Court-Supervised Sale
Teva acquired BioXcel’s neuroscience assets through a court-supervised sale process under the U.S. Bankruptcy Code.
Story updates
12:06:11 PM UTC
SquawkNews
Teva Acquired the Assets for $57.5 M Upfront and Up to $67.5 M in Contingent Payments >TEVA